<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82036">
  <stage>Registered</stage>
  <submitdate>22/05/2007</submitdate>
  <approvaldate>4/06/2007</approvaldate>
  <actrnumber>ACTRN12607000297426</actrnumber>
  <trial_identification>
    <studytitle>A multi centre, open label study to evaluate efficacy and safety of 1000 mg of rituximab on day 1 and 15 in patients with idiopathic thrombocytopenic purpura</studytitle>
    <scientifictitle>A multi centre, single arm, open label study to evaluate the efficacy and safety of 1000 mg fixed dose of rituximab on day one and fifteen among patients with chronic or relapsing idiopathic thrombocytopenic purpura</scientifictitle>
    <utrn />
    <trialacronym>R-ITP 1000</trialacronym>
    <secondaryid>ClinicalTrials.gov: NCT00475423</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Idopathic Thrombocytopenic Purpura</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Only one treatment, rituximab fixed dose of 1000 mg on day 1 and 15 given intravenously (IV).</interventions>
    <comparator>no comparator being used.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Response rate based on platelet count as determined by blood tests (full blood count).</outcome>
      <timepoint>Measured 8 weeks after day 1.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response</outcome>
      <timepoint>Measured monthly from week 8 up to 52 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety </outcome>
      <timepoint>As reported by patients at weekly study visits up to week 8</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Documented diagnosis of Idiopathic Thrombocytopaenic Purpura (ITP)  according to the American Society of Haematology (ASH) guidelines:
1. Chronic ITP requiring ongoing corticosteroid and/or immunosuppressive therapy (e.g. dexamethasone, prednisolone, danazol, azathioprine and/or cyclophosphamide) for more than 3 months to maintain platelet count &gt;30x10^9/L. Patients must have a documented platelet count of &gt;30x10^9/L and = 50x10^9/L within 7 days prior to first infusion.

OR

2. ITP in relapse (&gt; or = 1) (defined as a platelet count = 30x10^9/L), with first relapse occurring within 12 months of initial diagnosis and second relapse at any time thereafter. Patients must have a documented platelet count = 30x10^9/L and &gt;10x10^9/L within 7 days prior to first infusion.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. ITP diagnosed less than 6 weeks prior to consent.
2. Prior treatment with rituximab.
3. Multisystem autoimmune disease.
4. Lymphoproliferative disorders.
5. Drug-induced thrombocytopenia.
6. Pregnant or breast-feeding.
7. Human Immunodeficiency Virus (HIV) serology positive. 
8. Hepatitis B or Hepatitis C serology positive (unless due to vaccination).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>16/05/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>108</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Roche</primarysponsorname>
    <primarysponsoraddress>4-10 Inman Road, Dee Why, NSW, 2099 Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Roche</fundingname>
      <fundingaddress>4-10 Inman Road, Dee Why, NSW, 2099 Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>not applicable</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Review efficacy of giving rituximab on day 1 and 15 to see if platelet levels recover and how long a response last.  Patients will attend regular visits for the collection of blood samples</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Frankston Hospital.</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>James Scott</name>
      <address>Roche Products 
4-10 Inman Road Dee Why NSW 2099</address>
      <phone>+61 2 9454 9242</phone>
      <fax />
      <email>james_c.scott@roche.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>James Scott</name>
      <address>Roche Products 
4-10 Inman Road Dee Why NSW 2099</address>
      <phone>+61 2 9454 9242</phone>
      <fax />
      <email>james_c.scott@roche.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>James Scott</name>
      <address>Roche Products 
4-10 Inman Road Dee Why NSW 2099</address>
      <phone>+61 2 9454 9242</phone>
      <fax />
      <email>james_c.scott@roche.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>